On December 1, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (referred to as the “Company” or “Mindray”, SZSE: 300760) announced the completion of its acquisition of a 75% stake in Germany-based DiaSys Diagnostic Systems GmbH (“DiaSys”). Upon completion, DiaSys is now recognized as a majority-owned subsidiary of Mindray.

Broncus has entered an equity transfer agreement to acquire a 100% equity interest in Chinese device company Hangzhou Jingliang.

Switzerland's Roche (ROG.S) has agreed to pay an initial $7.1 billion to Roivant (ROIV.O) and Pfizer (PFE.N) for rights to a new inflammatory bowel disease drug, as it expands into new fields to offset falling oncology sales.

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash.

Abbott (NYSE: ABT) today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Diagnostic healthcare company New Day Diagnostics has announced the approval of an agreement to acquire Epigenomics to provide accessible and innovative diagnostic solutions.

Laborie Medical Technologies has entered a definitive agreement for the acquisition of medical device company Urotronic in a deal valued at up to $600m.

LabGenomics USA, a subsidiary of South Korean-based diagnostics firm LabGenomics, said Tuesday that it has acquired QDx Pathology for an undisclosed amount.

Abbott (NYSE: ABT) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.

Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.